15 long-form pieces. Each one is built on named trials, published price guides and regulator statements, with the date we read each source on the page. Newest: August 4, 2026.
Semaglutide's foundational patent expired 20 March 2026 in India, China, Brazil and South Africa and lapsed in Canada. US protection runs to at least 2032. The dates, market by market.
BPC-157, TB-500, ipamorelin, sermorelin, tesamorelin and the GLP-1s sit at wildly different evidence levels. A tiered map of what each actually has behind it.
Medicaid coverage of GLP-1s for obesity varies by state, and a state with no coverage changes the cheapest route entirely. Coverage type, cash routes and what to ask, state by state.
All three contain semaglutide. They differ in approved indication, maximum dose, route and price — and those differences decide coverage more than the molecule does.
Five free public databases settle whether a telehealth provider and its pharmacy are what they say. The checks, in order, and what each one can and cannot tell you.
STEP-1 reported about two-thirds of lost weight returned within a year of stopping. SURMOUNT-4 reported regain on withdrawal against continued loss on treatment. The numbers, and what they mean.
The manufacturer's direct self-pay channel, read from its own price guide: $149 to $499 depending on product and dose, with two rates that expire on stated dates.
Four pricing structures separate an advertised monthly figure from what lands on your card. How each works, and the four questions that surface all of them.
The FDA declared the semaglutide shortage resolved in February 2025. That ended the mass-compounding pathway. What remains is 503A patient-specific compounding, and it requires a documented reason.
Generic liraglutide referencing Victoza arrived in December 2024 and Saxenda in August 2025. It is the cheapest approved GLP-1 — and it produced 6.4% against semaglutide's 15.8% head to head.
A share of weight lost on any effective intervention is lean mass. What the imaging sub-studies reported, what they could not measure, and why no protocol is evidence-based yet.
Gastrointestinal effects cluster at dose increases rather than spreading evenly. What the trials reported, when discontinuation happens, and what the label says about the titration schedule.
Approved for HIV-associated lipodystrophy, not for general fat loss or anti-ageing. What the trials established, the labelled risks, and why it is not comparable to a GLP-1.
Delayed gastric emptying means a standard pre-operative fast may not empty the stomach. What anaesthesia guidance says, and why it applies to compounded products too.
A boxed warning, absolute contraindications and several situations requiring caution. What the labelling states and what an online intake should be asking you.